Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Showing 1 to 67 of 67

TitleReference numberPublishedLast updated
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Lung cancer: diagnosis and managementNG122
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTE12
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodulesDG46
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Microwave ablation for primary or metastatic cancer in the lungIPG716
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA761
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA760
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapyTA374
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)TA362
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancerTA347
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancerDG9
Irreversible electroporation for treating primary lung cancer and metastases in the lungIPG441
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancerTA258
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancerTA227
Percutaneous radiofrequency ablation for primary or secondary lung cancersIPG372
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancerTA192
Topotecan for the treatment of relapsed small-cell lung cancerTA184
Pemetrexed for the first-line treatment of non-small-cell lung cancerTA181
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)TA148
Pemetrexed for the treatment of non-small-cell lung cancerTA124

Results per page

  1. 10
  2. 25
  3. 50
  4. All